NCT03316482 is a Phase 4 clinical trial of Leuplin DPS 11.25mg in Central Precocious Puberty, sponsored by Jin Soon Hwang.

Who is sponsoring NCT03316482?

NCT03316482 is sponsored by Jin Soon Hwang.

What drugs are being tested in NCT03316482?

Interventions in NCT03316482: Leuplin DPS 11.25mg.

What condition does NCT03316482 study?

NCT03316482 studies Central Precocious Puberty.

Is NCT03316482 still recruiting?

NCT03316482 is currently completed. Last updated 2 June 2020.

Last reviewed 2020-06-02 · How we verify

NCT03316482

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

Completed Phase 4 Last updated 2 June 2020

What this trial tests

Phase 4 trial testing Leuplin DPS 11.25mg in Central Precocious Puberty in 58 participants. Completed in 30 December 2019.

Timeline

11 June 2015

Primary endpoint
29 August 2019

30 December 2019

Quick facts

Lead sponsor	Jin Soon Hwang
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	11 June 2015
Primary completion	29 August 2019
Estimated completion	30 December 2019
Sites	1 location across South Korea

Drugs / interventions tested

Leuplin DPS 11.25mg — full drug profile →

Conditions studied

Central Precocious Puberty — all drugs for Central Precocious Puberty →

Sponsor

Jin Soon Hwang — full company profile →

Who can join

Adults 4 to 9, any sex, with Central Precocious Puberty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter, open-label, prospective study to evaluate the safety and efficacy of leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious puberty

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03316482 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jin Soon Hwang
Last refreshed: 2 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03316482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing